Open AccessAccelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
Author(s) -
Ning YangMin,
Maher V. Ellen,
Beaver Julia A.,
Goldberg Kirsten B.,
Blumenthal Gideon M.,
Pazdur Richard
Publication year - 2018
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2017-0415
Subject(s) - medicine , immunotherapy , urothelial cancer , urothelial carcinoma , oncology , metastatic urothelial carcinoma , cancer , bladder cancer
Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are predictive of individual patient response to different immunotherapies.